Moteur de recherche d’entreprises européennes

Financement de l’UE (4 498 931 €) : Patients actifs dans la recherche et les dialogues pour une meilleure génération de médicaments : Promouvoir un engagement significatif des patients dans le cycle … Hor01/03/2018 Programme de recherche et d'innovation de l'UE « Horizon »

Texte

Patients actifs dans la recherche et les dialogues pour une meilleure génération de médicaments : Promouvoir un engagement significatif des patients dans le cycle de vie des médicaments pour de meilleurs résultats en matière de santé.

PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE. PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures. PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come. PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.


Agenzia Italiana Del Farmaco 50 000 €
Alexion Services Europe SPRL 0,00 €
Alzheimer Europe 248 500 €
Amgen Ltd. 0,00 €
BAYER AG 0,00 €
Eli Lilly and Company Ltd. 0,00 €
EUROPEAN AIDS TREATMENT GROUP e. V. 381 750 €
European Forum for Good Clinical Practice 198 000 €
Eurordis - Rare Diseases Europe 463 598 €
F. HOFFMANN-LA ROCHE AG 0,00 €
Federation Europeenne d'Associations et d'Industries Pharmaceutiques 0,00 €
Forum des Patients Europeens 702 516 €
Fundacio Privada Per A La Recerca i La Docencia Sant Joan de Deu 176 125 €
Glaxosmithkline Research & Development Ltd. 0,00 €
GRUNENTHAL GmbH 0,00 €
H. Lundbeck AS 0,00 €
Health Technology Assessment International Society 0,00 €
Institut de Recherches Internationales Servier 0,00 €
Instituto Aragones de Ciencias de La Salud 181 086 €
Janssen Pharmaceutica N.V. 0,00 €
Labcorp Early Development Laboratories Ltd. 0,00 €
MERCK KGaA 0,00 €
MERCK SHARP & DOHME Corp. 0,00 €
NOVARTIS PHARMA AG 0,00 €
Novo Nordisk A/S 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
STICHTING VU 458 438 €
Synapse Research Management Partners SL 399 595 €
Synergist Services 0,00 €
Teamit Research SL 73 903 €
The Association of the British Pharmaceutical Industry 0,00 €
The Chancellor, Masters and Scholars of the University of Oxford 621 593 €
THE Synergist 543 829 €
UCB Biopharma 0,00 €
VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER e. V. 0,00 €

https://cordis.europa.eu/project/id/777450

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.